TURKEL CATHERINE C. 4
4 · Novus Therapeutics, Inc. · Filed Nov 6, 2017
Insider Transaction Report
Form 4
TURKEL CATHERINE C.
Chief Development Officer
Transactions
- Award
Stock Option (Right to Buy)
2017-11-06+50,000→ 50,000 totalExercise: $4.21Exp: 2027-11-06→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]This option represents a right to purchase a total of 50,000 shares of the Issuer's Common Stock one quarter of which will become fully vested and exercisable on 11/6/2018, with the remaining 37,500 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.